{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=umeclidinium+bromide+%28UMEC%29", "query": { "intervention": "umeclidinium bromide (UMEC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=umeclidinium+bromide+%28UMEC%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T00:14:03.942Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03478696", "title": "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "budesonide/formoterol", "type": "DRUG" }, { "name": "albuterol/salbutamol", "type": "DRUG" }, { "name": "FF/UMEC/VI", "type": "DRUG" }, { "name": "Placebo to match budesonide/formoterol", "type": "DRUG" }, { "name": "tiotropium", "type": "DRUG" }, { "name": "Placebo to match FF/UMEC/VI", "type": "DRUG" }, { "name": "placebo to match tiotropium", "type": "DRUG" }, { "name": "ELLIPTA", "type": "DEVICE" }, { "name": "MDI", "type": "DEVICE" }, { "name": "HandiHaler", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 732, "start_date": "2018-06-25", "completion_date": "2019-03-18", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 42, "location_summary": "Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03478696" }, { "nct_id": "NCT05127304", "title": "A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Trelegy Ellipta", "type": "DEVICE" }, { "name": "Stiolto Respimat", "type": "DEVICE" }, { "name": "Furoate/Umeclidinium/Vilanterol", "type": "DRUG" }, { "name": "Tiotropium Bromide/Olodaterol", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 11316, "start_date": "2021-02-26", "completion_date": "2022-02-03", "has_results": true, "last_update_posted_date": "2023-11-13", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 1, "location_summary": "Eden Prairie, Minnesota", "locations": [ { "city": "Eden Prairie", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05127304" }, { "nct_id": "NCT03949842", "title": "Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists", "type": "DRUG" }, { "name": "Fluticasone furoate/umeclidinium/vilanterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 0, "start_date": "2019-06-27", "completion_date": "2022-11-30", "has_results": false, "last_update_posted_date": "2020-04-22", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 3, "location_summary": "Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah", "locations": [ { "city": "Waterbury", "state": "Connecticut" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Layton", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03949842" }, { "nct_id": "NCT02924688", "title": "A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FF/UMEC/VI (100/31.25/25) mcg", "type": "DRUG" }, { "name": "FF/UMEC/VI (100/62.5/25) mcg", "type": "DRUG" }, { "name": "FF/UMEC/VI (200/31.25/25) mcg", "type": "DRUG" }, { "name": "FF/UMEC/VI (200/62.5/25) mcg", "type": "DRUG" }, { "name": "FF/VI (100/25) mcg", "type": "DRUG" }, { "name": "FF/VI (200/25) mcg", "type": "DRUG" }, { "name": "Fluticasone/salmeterol (FSC)", "type": "DRUG" }, { "name": "Albuterol/salbutamol", "type": "DRUG" }, { "name": "ELLIPTA DPI", "type": "DEVICE" }, { "name": "DISKUS DPI", "type": "DEVICE" }, { "name": "METERED-DOSE INHALER (MDI)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2436, "start_date": "2016-10-13", "completion_date": "2019-02-22", "has_results": true, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 99, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924688" }, { "nct_id": "NCT01879410", "title": "A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI", "type": "DRUG" }, { "name": "FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS", "type": "DRUG" }, { "name": "Placebo DISKUS", "type": "DRUG" }, { "name": "Placebo NDPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 700, "start_date": "2013-06-13", "completion_date": "2014-01-09", "has_results": true, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 15, "location_summary": "Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Coeur d'Alene", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01879410" }, { "nct_id": "NCT02799784", "title": "An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "UMEC/VI", "type": "DRUG" }, { "name": "TIO/OLO", "type": "DRUG" }, { "name": "Albuterol/salbutamol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 236, "start_date": "2016-07-14", "completion_date": "2017-04-27", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 9, "location_summary": "Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Medford", "state": "Oregon" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02799784" }, { "nct_id": "NCT02164513", "title": "A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "fluticasone furoate (FF)", "type": "DRUG" }, { "name": "vilanterol (VI)", "type": "DRUG" }, { "name": "umeclidinium bromide (UMEC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 10355, "start_date": "2014-06-30", "completion_date": "2017-07-17", "has_results": true, "last_update_posted_date": "2018-10-10", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 269, "location_summary": "Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164513" }, { "nct_id": "NCT01817764", "title": "A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Umeclidinium/vilanterol", "type": "DRUG" }, { "name": "Fluticasone propionate/salmeterol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 707, "start_date": "2013-03-01", "completion_date": "2013-10-25", "has_results": true, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 9, "location_summary": "Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01817764" }, { "nct_id": "NCT02164539", "title": "Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF", "type": "DRUG" }, { "name": "UMEC", "type": "DRUG" }, { "name": "VI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2014-07-01", "completion_date": "2015-07-18", "has_results": true, "last_update_posted_date": "2017-10-11", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 14, "location_summary": "Newport Beach, California • San Diego, California • Upland, California + 11 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Sunset", "state": "Louisiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164539" }, { "nct_id": "NCT02119286", "title": "Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "FF", "type": "DRUG" }, { "name": "VI", "type": "DRUG" }, { "name": "UMEC", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 620, "start_date": "2013-10", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-04T00:14:03.942Z", "location_count": 14, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02119286" } ] }